Xenon Pharmaceuticals Inc
General ticker "XENE" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $3.2B
Xenon Pharmaceuticals Inc does not follow the US Stock Market performance with the rate: -6.8%.
Estimated limits based on current volatility of 2.3%: low 37.88$, high 39.67$
Factors to consider:
- Price in estimated range
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [27.42$, 51.50$]
- 2024-12-30 to 2025-12-30 estimated range: [25.77$, 48.86$]
Financial Metrics affecting the XENE estimates:
- Negative: Non-GAAP EPS, $ of -2.72 <= 0.10
- Negative: Operating profit margin, % of -100 <= 1.03
- Negative: Operating cash flow per share per price, % of -5.24 <= 2.35
- Negative: negative Net income
- Positive: -3.48 < Investing cash flow per share, $ of -1.75
- Negative: Industry operating cash flow per share per price (median), % of -23.87 <= 3.85
- Negative: Industry earnings per price (median), % of -26.04 <= 1.31
Short-term XENE quotes
Long-term XENE plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $18.44MM | $9.43MM | $0.00MM |
| Operating Expenses | $97.43MM | $138.58MM | $214.05MM |
| Operating Income | $-78.99MM | $-129.14MM | $-214.05MM |
| Non-Operating Income | $0.10MM | $3.89MM | $31.37MM |
| R&D Expense | $75.46MM | $105.77MM | $167.51MM |
| Income(Loss) | $-78.89MM | $-125.25MM | $-182.69MM |
| Taxes | $-0.01MM | $0.12MM | $-0.29MM |
| Profit(Loss) | $-78.88MM | $-125.37MM | $-182.39MM |
| Stockholders Equity | $550.03MM | $721.50MM | $927.92MM |
| Inventory | $2.77MM | $0.99MM | $0.00MM |
| Assets | $572.01MM | $754.15MM | $964.80MM |
| Operating Cash Flow | $-69.50MM | $-98.43MM | $-145.33MM |
| Capital expenditure | $2.05MM | $2.89MM | $5.62MM |
| Investing Cash Flow | $-246.77MM | $-296.00MM | $-117.17MM |
| Financing Cash Flow | $447.54MM | $278.47MM | $353.52MM |
| Earnings Per Share* | $-1.81 | $-2.07 | $-2.73 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.